G1/S Cell Cycle Checkpoint Defect in Lymphocytes from Patients with Alzheimer’s Disease
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Objective We compared the cell responsiveness of activated lymphocytes to rapamycin, which blocks the G1/S transition, between patients with Alzheimer’s disease (AD) and normal controls to assess the early phase control defect in cell cycle. MethodsaaBlood samples of 26 patients with AD and 28 normal controls were collected to separate peripheral lymphocytes. We measured the proportion of each cell cycle phase in activated lymphocytes using flow cytometry and evaluated the responsiveness of these lymphocytes to rapamycin. Results The patients with AD were older than the normal controls (AD 74.03±7.90 yr vs. control 68.28±6.21 yr, p=0.004). The proportion of G1 phase cells in the AD group was significantly lower than that in the control group (70.29±6.32% vs. 76.03±9.05%, p=0.01), and the proportion of S phase cells in the AD group was higher than that in control group (12.45±6.09% vs. 6.03±5.11%, p=0.001). Activated lymphocytes in patients with AD were not arrested in the G1 phase and they progressed to the late phase of the cell cycle despite rapamycin treatment, in contrast to those of normal subjects. Conclusion The patients with AD probably have a control defect of early phase cell cycle in peripheral lymphocytes that may be associated with the underlying pathology of neuronal death.
Abstract
Objective We compared the cell responsiveness of activated lymphocytes to rapamycin, which blocks the G1/S transition, between patients with Alzheimer’s disease (AD) and normal controls to assess the early phase control defect in cell cycle. MethodsaaBlood samples of 26 patients with AD and 28 normal controls were collected to separate peripheral lymphocytes. We measured the proportion of each cell cycle phase in activated lymphocytes using flow cytometry and evaluated the responsiveness of these lymphocytes to rapamycin. Results The patients with AD were older than the normal controls (AD 74.03±7.90 yr vs. control 68.28±6.21 yr, p=0.004). The proportion of G1 phase cells in the AD group was significantly lower than that in the control group (70.29±6.32% vs. 76.03±9.05%, p=0.01), and the proportion of S phase cells in the AD group was higher than that in control group (12.45±6.09% vs. 6.03±5.11%, p=0.001). Activated lymphocytes in patients with AD were not arrested in the G1 phase and they progressed to the late phase of the cell cycle despite rapamycin treatment, in contrast to those of normal subjects. Conclusion The patients with AD probably have a control defect of early phase cell cycle in peripheral lymphocytes that may be associated with the underlying pathology of neuronal death.
참고문헌 (27)
- Elias MF., "The preclinical phase of alzheimer disease: a 22-year prospective study of the Framingham Cohort", Arch Neurol, 57, pp.808~813 (2000)
- Raina AK., "The role of cell cyclemediated events in Alzheimer’s disease", Int J Exp Pathol, 80, pp.71~76 (1999)
- Cotman CW., "A potential role for apoptosis in neurodegeneration and Alzheimer’s disease", Mol Neurobiol, 10, pp.19~45 (1995)
- Rissman RA., "Caspase-cleavage of tau is an early event in Alzheimer disease tangle pathology", J Clin Invest, 114, pp.121~130 (2004)
- Gladkevich A., "Lymphocytes as a neural probe: potential for studying psychiatric disorders", Prog Neuropsychopharmacol Biol Psychiatry, 28, pp.559~576 (2004)
- Nagy Z., "Cell cycle kinesis in lymphocytes in the diagnosis of Alzheimer’s disease", Neurosci Lett, 317, pp.81~84 (2002)
- Araga S., "Lymphocyte proliferation and subpopulations in dementia of the Alzheimer type", Jpn J Med, 29, pp.572~575 (1990)
- Se Chang Yoon, "Altered Cell Viability and Proliferation Activity of Peripheral Lymphocytes in Patients with Alzheimer’s Disease", PSYCHIATRY INVESTIGATION, 7(1), pp.68~71 (2010), 대한신경정신의학회
- Cummings JL., "Alzheimer disease", JAMA, 287, pp.2335~2338 (2002)
- Nagy Z., "The last neuronal division: a unifying hypothesis for the pathogenesis of Alzheimer’s disease", J Cell Mol Med, 9, pp.531~541 (2005)
- Herrup K., "Divide and die: cell cycle events as triggers of nerve cell death", J Neurosci, 24, pp.9232~9239 (2004)
- Nagy Z., "Cell cycle regulatory failure in neurones: causes and consequences", Neurobiol Aging, 21, pp.761~769 (2000)
- Kang Y., "A validity study on the Korean Mini-Mental State Examination (K-MMSE) in dementia patients", J Korean Neurol Assoc, 15, pp.300~308 (1997)
- Morris JC., "The Clinical Dementia Rating (CDR): current version and scoring rules", Neurology, 43, pp.2412~2414 (1993)
- 구형모, "일상활동평가-복합(Seoul-Instrumental Activities of Daily Living ; S-IADL)의 신뢰도 및 타당도 연구", 신경정신의학, 43(2), pp.189~199 (2004), 대한신경정신의학회
- Ku HM., "A study on the reliability and validity of Seoul-Activities of Daily Living (S-ADL)", J Korean Geriatr Soc, 8, pp.206~214 (2004)
- Christensen KJ., "A cognitive battery for dementia: Development and measurement characteristics", Psychol Assess, 3, pp.168~174 (1991)
- Ivnik RJ., "Kokmen E. Mayo’s older americans normative studies: Updated AVLT norms for ages 56 to 97", Clin Neuropsychol, 6, pp.83~104 (1992)
- Petersen RC., "Mild cognitive impairment as a diagnostic entity", J Intern Med, 256, pp.183~194 (2004)
- Dittmer D., "Human cytomegalovirus infection inhibits G1", S transition, 1997, pp.71, 1629~1634
- Gardner LB., "Hypoxia inhibits G1", S transition through regulation of p27 expression, 2001, pp.276, 7919~7926
- 구형모, "7분 선별검사(7 Minute Screen Test) 각 하위 척도의 임상적 유용성", 신경정신의학, 44(2), pp.253~258 (2005), 대한신경정신의학회
- Battaglia M., "Rapamycin selectively expands CD4+CD25+FoxP3+ regulatory T cells", Blood, 105, pp.4743~4748 (2005)
- Meikrantz W., "Apoptosis and the cell cycle", J Cell Biochem, 58, pp.160~174 (1995)
- McShea A., "Re-entry into the cell cycle: a mechanism for neurodegeneration in Alzheimer disease", Med Hypotheses, 52, pp.525~527 (1999)
- Richartz-Salzburger E., "Altered lymphocyte distribution in Alzheimer’s disease", J Psychiatr Res, 41, pp.174~178 (2007)
- Mizrahi C., "Differential cAMP levels and serotonin effects in blood peripheral mononuclear cells and lymphocytes from major depression patients", Int Immunopharmacol, 4, pp.1125~1133 (2004)